IQVIA Holdings Inc.
Analysis
After two years of cautious pharma spending, IQVIA's orders, guidance and AI pitch all turned up together. What has not turned is the profit it keeps from each dollar of sales.How much of the 2026 revenue raise comes from acquisitions?
- Demand recovered, and guidance followed it up.
RFP flow grew double digits and net bookings hit a record, with 12-month orders rising in each of the past four quarters. Management raised EPS in Q1 FY2026, then revenue and profit together in Q2, crediting operations rather than currency.
- AI flipped from feared disruptor to sales pitch.
A February article had investors asking whether AI would gut the business. By Q2 IQVIA had 294 agents live and 19 of the top 20 drugmakers using them, and management called AI a tailwind it already sees in win rates.How much of the win-rate gain is AI versus pricing?
- Profit per dollar of sales is still not growing.
In Q2, internal efficiency gains lifted margin while pass-through work, billed at cost with no profit, pulled it back down. They cancelled out, and management expects flat margins this year, so sales can rise without profit rising faster.How much of 2026's growth is low-margin pass-through work?
- Clinical bookings momentumThe bull case is that demand for outsourced clinical trials has turned and IQVIA is winning a larger share of awards from both large drugmakers and biotechs.
- AI agents in client workflowsA second support is IQVIA's proprietary health data and AI agents, which management says win contracts outright and are used inside most of the largest drugmakers.
- Emerging biotech fundingBiotech funding has rebounded and IQVIA says it wins more of that segment's trial work than any competitor, so a funding recovery feeds straight into bookings.
- Lumpy quarterly trial awardsThe bear case is that quarterly awards swing with a handful of trial decisions and pass-through billing, so reported book-to-bill says little about the next year's revenue.
- Slow pharma spending decisionsLarge drugmakers still sign trials more slowly than they did before the recent policy and funding turmoil, which delays when new awards turn into revenue.
- Flat margins on growing revenueRevenue growth is not reaching the bottom line, because pass-through costs carry no profit and acquired businesses dilute margins, leaving profitability roughly flat.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$15K | Aug 26 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 23 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$15K | May 22 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$1K | May 21 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 23 | May 13 |
Congressional trading data provided by QuiverQuant
How IQVIA Holdings turned $16.3B of revenue into $2.2B of operating income.
| Revenue | ||
|---|---|---|
| Research And Development Solutions | $8.9B | ▲ 4.33% YoY |
| Technology And Analytics Solutions | $6.6B | ▲ 7.56% YoY |
| Contract Sales And Medical Solutions | $788.0M | ▲ 9.75% YoY |
| Total revenue | $16.3B | |
| Gross profit | $5.4B | 33.3% |
| Operating income | $2.2B | 13.4% |